What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide investors with recast historical financial information that reflects the separation of Becton Dickinson's (BD) Diabetes Care business (embecta) as discontinued operations. This allows for a clearer view of BD's standalone performance from its continuing operations.

What are 'non-GAAP measures' and why is BD using them?

Non-GAAP measures are financial metrics that differ from U.S. generally accepted accounting principles (GAAP). BD is using them to adjust for certain 'specified items' that management believes are outside of the company's underlying operational results or affect period-to-period comparability. These include costs related to new EU regulations, integration costs, and litigation. BD believes these measures offer a better understanding of underlying business trends and operational performance.

What are the 'European regulatory initiative-related costs' mentioned?

These are significant, unusual costs incurred by BD to develop processes and systems for initial compliance with the European Union's new Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation. BD considers these one-off costs that are separate from ongoing operational performance.

How should investors interpret the information in this filing?

Investors should review the recast historical financial information to understand BD's performance excluding the divested Diabetes Care business. They should also carefully consider the provided non-GAAP measures, understanding the adjustments made. However, BD strongly advises investors to read these non-GAAP measures in conjunction with their official GAAP financial statements, as the excluded items can materially affect reported net income and earnings per share.

BDX 8-K: Earnings & Results

Summary

Becton, Dickinson and Company (BDX) has filed an 8-K report on April 14, 2022, primarily to provide investors with recast historical financial information following the separation of its Diabetes Care business (embecta) on April 1, 2022. This recast information presents BD's former Diabetes Care business as discontinued operations, offering a clearer view of the company's ongoing business performance from continuing operations. Furthermore, the filing includes non-GAAP financial measures that adjust for various items such as purchase accounting adjustments, integration and restructuring costs, litigation matters, and notably, significant costs related to initial compliance with new European Union Medical Device Regulations. BD's management believes these non-GAAP measures provide valuable insights into underlying business trends and operational performance, aiding investors in understanding year-over-year comparisons and future prospects. However, the company strongly advises investors to review these non-GAAP measures alongside their GAAP financial statements due to potential material impacts of excluded items.

Key Highlights

1BDX has completed the separation of its Diabetes Care business (embecta) into a separate public company as of April 1, 2022.
2The company is providing recast historical financial information to reflect embecta as discontinued operations.
3This recast aims to present BD's standalone operating results from continuing operations for better historical baseline analysis.
4The filing introduces non-GAAP financial measures that adjust for specified items, including significant costs related to new EU Medical Device Regulations.
5These non-GAAP measures are intended to help investors understand underlying business trends and improve period-over-period comparability.
6Management utilizes these non-GAAP measures for performance evaluation and forecasting, alongside GAAP results.
7Investors are strongly encouraged to review both GAAP and non-GAAP measures, as excluded items can materially impact financial results.

BECTON DICKINSON & CO 8-K Report, Financial Results (Apr 14, 2022)

Summary

Key Highlights

Frequently Asked Questions